Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who’s Buying and Why?

You're looking at Vivos Therapeutics, Inc. (VVOS) and seeing a classic small-cap conundrum: explosive top-line growth mixed with a challenging bottom line, so you're asking who's actually buying this story. Honestly, the investor profile is a fascinating mix of high-conviction small funds and speculative retail traders, all keyed into the company's strategic pivot toward medical sleep practices. For the third quarter of 2025, Vivos posted revenue of $6.8 million, a massive 76% jump year-over-year, largely thanks to the Sleep Center of Nevada acquisition, but still reported a net loss of $5.4 million. This mixed picture is reflected in the ownership structure: institutional investors hold a relatively small slice, around 10.57% of the shares, but that total of over 692,833 shares is spread across 34 different funds, including Connective Capital Management, LLC and Vanguard Group Inc., who have been activly adding to their positions. What this tells you is that while the stock has extreme volatility-a Beta of 13.26 is defintely a wild ride-a core group of professional money managers is betting on the operational shift to direct patient care and the potential of their oral appliances, which average just over $5,000 per case. Do the growth numbers justify the risk, and who are the specific players making the big moves? Let's break down the shareholder register to see where the real conviction lies.

Who Invests in Vivos Therapeutics, Inc. (VVOS) and Why?

The investor base for Vivos Therapeutics, Inc. (VVOS) is primarily a mix of high-conviction retail traders and company insiders, with a smaller but influential core of institutional funds. This ownership structure reflects the company's position as a micro-cap medical technology stock undergoing a high-risk, high-reward strategic pivot.

You need to know that nearly 60% of the company is held by individual investors, meaning the stock's daily price action can be highly volatile. This is a classic profile for a company whose narrative is centered on a major turnaround. The total outstanding shares entitled to vote as of the September 8, 2025 record date was 7,504,807 shares.

Key Investor Types: A High-Conviction Retail Base

The ownership breakdown for Vivos Therapeutics, Inc. is heavily skewed toward individual investors and company management. This is not a stock dominated by massive mutual funds; it's a story stock where the belief in the strategic pivot drives the capital. Here's the quick math on who owns the float:

• Retail/Public Investors: Approximately 59.90%
• Insider Ownership: Approximately 29.53%
• Institutional Ownership: Approximately 10.57%

The high insider ownership of nearly 30% is a double-edged sword: it shows management's skin in the game, but it also means a large portion of the stock is illiquid, which can amplify price swings. Institutional investors, including names like Vanguard Group Inc and Geode Capital Management, Llc, tend to be passive index funds or small-cap specialists, holding a combined total of around 692,833 shares.

Investment Motivations: The Strategic Pivot and Growth Narrative

Investors are attracted to Vivos Therapeutics, Inc. not for dividends-it is a loss-making growth company-but for the potential exponential return if its new business model succeeds. The core motivation is the company's pivot to a direct-to-patient model via medical sleep practice acquisitions and strategic alliances.

The Q3 2025 results provided the concrete evidence for this narrative: Revenue surged 76% year-over-year to $6.8 million, driven by the June 2025 acquisition of The Sleep Center of Nevada (SCN). This move is seen as an inflection point, shifting away from reliance on the dental channel to a model that puts their FDA-cleared oral appliances directly in front of Obstructive Sleep Apnea (OSA) patients. The promise is that this new model will lead to cash flow break-even in 2026, despite the Q3 2025 net loss widening to $5.4 million.

• Growth Prospects: 76% YoY revenue growth in Q3 2025, validating the SCN acquisition strategy.
• Market Position: The company's Complete Airway Repositioning and Expansion (CARE) devices are FDA-cleared for all severity levels of adult OSA and moderate-to-severe OSA in children.
• Speculative Turnaround: Betting on the company's ability to execute on its new strategy and convert its current net loss of $14.3 million (year-to-date through Q3 2025) into future profit.

If you want to understand the full scope of the company's long-term vision, you should review their Mission Statement, Vision, & Core Values of Vivos Therapeutics, Inc. (VVOS).

Investment Strategies: Speculative Growth and Short-Term Trading

The typical investment strategies seen in Vivos Therapeutics, Inc. are dominated by speculative growth and short-term trading, which is common for a micro-cap stock with a high beta of 13.26, indicating extreme volatility compared to the broader market.

Long-Term Growth Investors: These investors are the ones holding the largest institutional positions, like the mutual funds. They are betting on the long-term success of the strategic pivot, accepting the current financial risks-including the low cash reserve of $3.1 million as of September 30, 2025-for a multi-year payoff. They view the company as a potential disruptor in the sleep apnea market, which is a massive opportunity.

Short-Term Traders and Speculators: This group, largely comprising the 59.90% retail ownership, capitalizes on the stock's volatility. The low share price of $2.36 as of November 19, 2025, and high trading volume make it attractive for short-term plays. The short interest is relatively low at 4.12% of the public float as of October 31, 2025, with a short interest ratio of only 1.2 days to cover, meaning a significant short squeeze is defintely not the primary strategy, but volatility trading is.

The key action for you, as an investor, is to track the execution of the new medical acquisition model, specifically the contribution margin and the timeline for cash flow break-even in 2026. That's the real metric that will determine if the stock is a long-term growth story or just a short-term trade.

Institutional Ownership and Major Shareholders of Vivos Therapeutics, Inc. (VVOS)

You're looking at Vivos Therapeutics, Inc. (VVOS) and trying to figure out if the big money is buying into the turnaround story. The short answer is: institutional investors are split, but the recent buying suggests a cautious nod to the company's strategic pivot. As of the Q3 2025 filings, institutional ownership is relatively low, holding about 692,833 total shares, but the recent activity is what matters.

The total institutional stake is small, especially when compared to a BlackRock-sized portfolio, which often holds billions in a single stock. For VVOS, the total institutional ownership hovers around the 5.01% to 10.57% range, depending on how you count it. This low percentage is a red flag for some, signaling limited institutional confidence, but it also means any significant buying can move the stock. The reality is, with a beta of 13.26, this stock is extremely volatile, and the big funds are treating it like a high-risk, high-reward bet on the company's new business model.

Top Institutional Investors: Who's Buying In?

The institutional investor landscape for Vivos Therapeutics is dominated by smaller, more specialized funds and large index trackers. These are the firms that have filed 13F forms with the SEC, disclosing their holdings as of September 30, 2025. It's important to see who is making a fresh bet on the company's shift to acquiring medical sleep practices.

Here's a look at the largest reported positions from the Q3 2025 filings:

Changes in Ownership: The Strategic Pivot Effect

The Q3 2025 data shows a clear divergence: some funds are running for the exits, but others are making a fresh entry. This tells me the market is debating the success of the company's strategic shift. You see 34 institutional owners holding a total of 692,833 shares, but the net change is mixed.

The buyers are betting on the new model. Connective Capital Management, LLC and Strategic Wealth Investment Group, LLC, for example, initiated substantial new positions of 200,000 and 100,000 shares, respectively. Plus, Vanguard Group Inc., a massive index fund player, more than doubled its position, adding 48,827 shares for a 114.5% increase. This buying activity aligns directly with the company's Q3 2025 revenue surge.

But there's a flip side. Other large institutions reduced their exposure significantly:

• UBS Group AG removed 142,699 shares in Q3 2025.
• Anson Funds Management LP completely exited its position in Q2 2025, removing 242,583 shares.

Here's the quick math: the new buyers are essentially replacing the funds that are skeptical of the long-term viability or the cost of the pivot. The new money is a vote of confidence in the top-line growth, but the sellers are worried about the bottom line.

Impact of Institutional Investors on Strategy and Stock

The role of these investors is two-fold: they provide essential capital and they act as a market signal. The buying in Q3 2025 is a direct endorsement of the company's strategic decision to pivot its sales model toward acquiring and affiliating with medical sleep practices, like the June 2025 acquisition of The Sleep Center of Nevada. That acquisition helped drive the Q3 2025 revenue up 76% year-over-year to $6.8 million.

However, the skepticism from sellers like UBS Group AG is grounded in the financial reality of that strategy. The net loss for Q3 2025 widened to $5.4 million, and the company's debt-to-equity ratio is high at 2.53. Large institutional investors, especially those who file a Schedule 13D (indicating an activist stake), can pressure management on this cash burn. The current institutional base is largely passive (Schedule 13G filers like Vanguard), meaning they are not actively trying to change the strategy, but their continued presence is crucial for market liquidity and stability.

The key takeaway is that the institutional money is supporting the direction of the business-the strategic collaborations and revenue growth-but remains cautious about the execution and the current financial health. You can find more detail on the company's background and financial path in Vivos Therapeutics, Inc. (VVOS): History, Ownership, Mission, How It Works & Makes Money. The next step for you is to monitor the Q4 2025 filings to see if the net buying trend continues, or if the widening net loss scares away the new money.

Key Investors and Their Impact on Vivos Therapeutics, Inc. (VVOS)

You're looking at Vivos Therapeutics, Inc. (VVOS) and want to know who's really backing the company and what their moves mean for the stock. The short answer is that institutional ownership is low, around 5.01% of the shares outstanding, but the key players are directly funding and validating the company's strategic pivot toward medical sleep practices, which is the big story for 2025.

The investor base is a mix of small funds, index trackers, and one critical strategic partner, reflecting the company's small-cap, growth-by-acquisition profile. As of the latest filings, Vivos Therapeutics, Inc. has 34 institutional owners holding a total of 692,833 shares. That's a low float, which means any large buying or selling can have an outsized effect on the stock price. Honestly, this stock is defintely more volatile because of that.

The most influential investor right now isn't a massive mutual fund but an affiliate of Cynica Partners, which provided crucial equity financing in 2025. This capital infusion directly supports the company's new business model, shifting away from a reliance on dental-only distribution toward acquiring and managing medical sleep centers, like the June 2025 acquisition of The Sleep Center of Nevada (SCN).

The Institutional Landscape: Who's Buying and Selling?

While the overall institutional percentage is modest, a few names stand out in the ownership structure. These firms are largely passive or tactical players, but their recent trading activity gives us a window into market sentiment following the strategic pivot and the Q3 2025 earnings release on November 19, 2025.

Here's a quick look at the major institutional holders and their recent actions, which were mixed in the third quarter:

• Connective Capital Management, LLC: A notable recent buyer, adding 200,000 shares in Q3 2025, a move estimated to be worth around $620,000. This suggests confidence in the new, integrated sleep center model.
• Vanguard Group Inc and Geode Capital Management, Llc: These are primarily index-tracking funds that hold shares as part of their broader small-cap or extended market index portfolios. They are passive investors, so their holdings reflect Vivos Therapeutics, Inc.'s inclusion in an index, not a specific, active investment thesis.
• ANSON FUNDS MANAGEMENT LP: Showed a significant reduction, removing 242,583 shares in Q2 2025.
• UBS GROUP AG: Also reduced their position, removing 142,699 shares in Q3 2025.

The selling from Anson and UBS, alongside the buying from Connective, tells a story of divergence: some funds are exiting the stock as the company transitions, while others are buying into the new strategy's potential. This is common during a major business model change. You need to decide which side of that trade you want to be on.

Investor Influence and The 2025 Strategic Pivot

The influence of investors on Vivos Therapeutics, Inc. is less about activist demands and more about providing the capital required for the strategic shift. The company's financial health is tight-it reported a net loss of $5.4 million in Q3 2025, and cash and cash equivalents were only $3.1 million as of September 30, 2025. This means financing partners like Cynica Partners have significant leverage because their capital is essential for growth.

Here's the quick math on the strategic shift: Q3 2025 Revenue jumped to $6.8 million, a 76% year-over-year increase, largely driven by the SCN acquisition. The SCN acquisition contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in new treatment center revenue in Q3 2025 alone. This revenue acceleration is the direct result of the strategy the key investors have backed with their capital.

What this estimate hides is the high insider ownership, which stands at approximately 9.37% of the outstanding shares. This high level of insider ownership means management's interests are closely aligned with shareholders, but it also gives them significant voting power in decisions, such as the director elections and the approval of the 2024 Omnibus Equity Incentive Plan amendment that occurred in November 2025. For a deeper dive into the company's foundation and business model, you should check out Vivos Therapeutics, Inc. (VVOS): History, Ownership, Mission, How It Works & Makes Money.

The takeaway is that the most impactful investors are the ones providing the financial runway for the strategic shift, like Cynica Partners, and the insiders who control a substantial portion of the vote. Their collective action is to push the company toward a more integrated, higher-margin revenue model, accepting short-term losses for long-term growth potential.

Next step: Analyze the Q3 2025 earnings call transcript to better understand management's guidance on achieving cash flow break-even, which is what all these investors are watching for.

Market Impact and Investor Sentiment

You're looking at Vivos Therapeutics, Inc. (VVOS) and seeing a stock that's definitely in the middle of a major business model pivot, and that makes investor sentiment a tricky read. It's not a simple 'buy' or 'sell' right now; it's a 'wait and see if the new strategy pays off' situation, which translates to mixed signals from the major players.

The institutional ownership is relatively low for a NASDAQ-listed company, sitting at approximately 10.57% of the float as of the most recent filings. This means the stock is highly susceptible to volatility, which is confirmed by its high Beta of 13.26. That's an extremely volatile stock. The largest shareholders are not traditional mutual funds but rather strategic investors like V-Co Investors 2 Llc, holding 11.03% of shares, and SP Manager LLC, with 6.86% as of June 2025. Their stake is a vote of confidence in the long-term vision, but it also means the stock price can swing wildly on small news, so be prepared for a bumpy ride.

• V-Co Investors 2 Llc: 11.03% ownership.
• SP Manager LLC: 6.86% ownership.
• Total Institutional Ownership: Approximately 10.57%.

Recent Market Reactions to Ownership Moves

The market has been reacting to Vivos Therapeutics, Inc.'s shift from a dental-only distribution model to one focused on acquiring and managing medical sleep practices, like The Sleep Center of Nevada (SCN). The recent Q3 2025 earnings announcement on November 19, 2025, showed the immediate impact of this strategy, and the market reaction was a perfect example of mixed sentiment.

The company reported a strong 76% year-over-year jump in Q3 2025 revenue, hitting $6.8 million, largely driven by the SCN acquisition. That's a huge growth number. But spending to support this expansion isn't cheap: the net loss for the quarter was $5.4 million, and operating expenses soared 74% year-over-year. Following the news, the stock dropped 4.45% during regular trading hours, closing at $2.47, but then it bounced back, rising 1.21% in after-hours trading. This tells you investors are torn: they love the revenue growth but hate the cash burn. Here's the quick math on the cash situation: cash and cash equivalents were only $4.4 million as of June 30, 2025.

Analyst Perspectives: Mapping Risk to Reward

The analyst community is generally bullish on the company's strategic pivot, despite the short-term financial pain. Two analysts covering the stock as of November 2025 have a consensus rating of 'Strong Buy'. They are looking past the current losses to the potential of the new direct-to-patient model. The average price target is set at $6.25, which implies a significant upside from the recent trading price.

To be fair, a wider view shows some caution. Other analysts suggest a 'Hold' or 'Reduce' consensus, recognizing the risk inherent in the company's financial health, including a high debt-to-equity ratio of 2.53. The key opportunity they see is the high patient demand for the Vivos Method-with nearly two-thirds of SCN patients choosing it over traditional CPAP, and an average case value exceeding $5,000. This is a powerful data point showing product-market fit. You can read more about this strategic shift and the company's core business model in Vivos Therapeutics, Inc. (VVOS): History, Ownership, Mission, How It Works & Makes Money.

The table below summarizes the core financial and analyst data for your decision-making:

The bottom line is this: key investors are buying into the growth story, but the stock's high volatility and negative cash flow mean you need to defintely size your position for risk. Your clear action is to track the Q4 2025 results for a continued revenue ramp and any sign of the operating loss narrowing.